



Grebely, J., Tran, L., Degenhardt, L., Dowell-Day, A., Santo, T., Larney, S., Hickman, M., Vickerman, P., French, C., Butler, K., Gibbs, D., Valerio, H., Read, P., Dore, G. J., & Hajarizadeh, B. (2021). Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis. *Clinical Infectious Diseases*, 73(1), e107-e118. Article ciaa612. <https://doi.org/10.1093/cid/ciaa612>

Peer reviewed version

Link to published version (if available):
[10.1093/cid/ciaa612](https://doi.org/10.1093/cid/ciaa612)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at <https://doi.org/10.1093/cid/ciaa612>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis

Jason Grebely¹, Lucy Tran², Louisa Degenhardt², Alexander Dowell-Day², Thomas Santo Jr², Sarah Larney², Matthew Hickman³, Peter Vickerman³, Clare French³, Kerry Butler^{2,4}, Daisy Gibbs², Heather Valerio¹, Phillip Read⁵, Gregory J. Dore¹, and Behzad Hajarizadeh¹

¹The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; ²National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia; ³Population Health Sciences, University of Bristol, Bristol, England; ⁴Discipline of Addiction Medicine, The University of Sydney, Sydney, NSW, Australia; ⁵Kirketon Road Centre, Sydney, NSW, Australia.

Key words: HCV, PWID, IDU, care cascade, injecting drug use, therapy

Running head: OAT and HCV care cascade in PWID

Word count: 2,991/3,000 words

Abstract word count: 245/250 words

Corresponding author

Professor Jason Grebely

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

Phone: +61-2-9385-0957

Fax: +61-2-9385-0876

email: jgrebely@kirby.unsw.edu.au

Alternate Corresponding author

Dr. Behzad Hajarizadeh

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

Phone: +61-2-9385-9208

Fax: +61-2-9385-0876

email: bhajarizadeh@kirby.unsw.edu.au

Summary

Opioid agonist therapy (OAT) was associated with increased HCV testing and treatment among PWID, but not treatment completion or sustained virologic response. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further elimination efforts.

ABSTRACT

Background: People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. **Methods:** Bibliographic databases and conference presentations were searched for studies assessing the association between OAT and HCV testing, treatment, and treatment outcomes [direct-acting antiviral (DAA) therapy only] among people who inject drugs (in the past year). Meta-analysis was used to pool estimates. **Results:** Among 9,877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in one study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing [4 studies; odds ratio (OR), 1.80; 95% CI:1.36, 2.39), HCV RNA testing among those who were HCV antibody positive (2 studies; OR, 1.83; 95% CI:1.27, 2.62), and DAA treatment uptake among those who were HCV RNA positive (7 studies; OR 1.53; 95% CI: 1.07, 2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). **Conclusions:** Opioid agonist therapy can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts.

INTRODUCTION

Globally, 6.1 million people who inject drugs (PWID) are estimated to be living with hepatitis C virus (HCV) infection [1, 2]. The development of simple, effective direct-acting antiviral treatments (DAA) for the treatment of HCV infection [3] has been transformative, with evidence that DAAs are having a population-level impact on liver disease burden in settings where treatment scale-up has been broad at the population-level [4-7]. The World Health Organization (WHO) has set a goal to eliminate HCV infection as a global public health threat [8]. However, in many settings, HCV testing and treatment uptake remain below the WHO elimination targets, especially among PWID [8]. People who have injected drugs comprise the majority of existing infections in many countries [1, 2, 9]. Strategies to improve HCV testing and treatment outcomes for PWID, therefore, are critical for global HCV elimination efforts.

Opioid agonist therapy (OAT) improves antiretroviral therapy outcomes for HIV infection [10] and reduces risk of HIV and HCV acquisition [11, 12]. It is hypothesized that OAT may similarly increase engagement of PWID in the HCV care cascade. Although there are studies evaluating the uptake of HCV testing [13-20] and treatment uptake [14, 16, 20-24] among PWID, to our knowledge, the association between OAT and HCV testing, treatment uptake and treatment outcomes has not been systematically reviewed. Understanding the impact of OAT on the cascade of HCV care is critical to inform the implementation of successful strategies to enable progress towards global HCV elimination efforts among PWID.

In order to address this gap, we conducted a systematic review: 1) to evaluate the association between OAT and HCV testing and treatment uptake among PWID; and 2) to evaluate the association between OAT and adherence, treatment completion and sustained virologic response (SVR) following DAA treatment among PWID.

Methods

The study is reported in accordance with PRISMA [25], and the protocol was registered with PROSPERO (CRD42019138921).

Eligibility criteria

We included observational (cohorts and cross-sectional studies) or experimental studies investigating HCV testing and treatment, if the study met the following criteria: population of people with recent injecting drug use (injecting in the previous 12 months, including active/ongoing/current drug use); reported a comparison of outcomes among people who had and had not received OAT with either methadone or buprenorphine [ever or currently/recently (past 6 months)]; and reported one of the following outcomes: HCV antibody testing [ever or recently (past year)], HCV RNA testing [ever or recently (past year)], HCV treatment uptake (interferon-based and DAA), and DAA HCV treatment outcomes (adherence, completion, and SVR).

Information sources and search

Literature searches of five bibliographic databases, including Medline (PubMed), Scopus, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO were performed. Presentations at key viral hepatitis conferences were searched, including the International Liver Congress, The Liver Meeting, the Conference on Retroviruses and Opportunistic Infections, and the International Conference on Hepatitis Care in Substance Users. Reference lists of the articles included in the analysis, and relevant review articles were hand searched. Forward citation tracking was carried out using Scopus. Searches were performed in September 2018. For searches of HCV testing and treatment uptake, there was no time restriction. For searches of DAA treatment outcomes, searches were limited to studies

published since January 2013 (interferon-free DAA therapies available after this date). Combinations of search terms relating to HCV, drug use, OAT, HCV testing, and treatment were used (Appendix, pp. 2-3).

Study selection

Records identified through primary searches were screened by title and abstract after the removal of duplicates. The full text of potentially eligible records were retrieved, reviewed, and eligible studies included. In the case of multiple publications of one study, the one with the most up-to-date data was included.

Data collection process and data items

Data extracted included study characteristics, participant characteristics, testing outcomes, treatment uptake, and treatment outcomes (Appendix pp 4-7). Authors were contacted if supplementary data were required and updated/unpublished data were used in analyses.

Risk of bias in individual studies

The risk of bias for the included studies was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool [26]. Studies were ranked as having low, moderate, serious, or critical risk of bias across seven domains, and the overall risk of bias was derived.

Study selection, data extraction, and risk of bias appraisal was undertaken by two reviewers independently (study selection: JG and BH; data extraction: AD, LT, TS and JG; and risk of

bias appraisal: HV and LT), with discrepancies discussed with a third reviewer (study selection:LD; data extraction: BH; and risk of bias appraisal: LD).

Synthesis of results

The primary outcomes of interest were recent or ever HCV antibody testing, recent or ever HCV RNA testing (among those HCV antibody positive), HCV treatment uptake (among those HCV RNA positive), and DAA treatment outcomes (adherence, completion and SVR). Treatment completion was defined as completion of the full course of the prescribed treatment among those who initiated treatment. SVR was defined as unquantifiable HCV RNA at 12 or 24 weeks after the end of treatment for those who initiated treatment (intent-to-treat). The proportion of people with each outcome of interest was assessed and odds ratios (OR) were calculated for the association between: 1) ever having received OAT; and 2) currently received OAT on each outcome. For HCV treatment uptake, additional analyses were performed to evaluate the association between OAT and DAA treatment. For each study, the outcome measures and corresponding standard errors and 95% confidence intervals (95% CI) were calculated.

Meta-analysis was used to synthesize the outcome measure estimates. Heterogeneity across studies was assessed using the I^2 statistic, with an I^2 of less than 25%, 25–75%, and more than 75% considered as low, moderate, and high heterogeneity, respectively [27]. Random effect models were used when heterogeneity was medium or high ($I^2 \geq 25\%$).

Logit transformed outcome estimates were used in all meta-analyses, while the estimates were back-transformed for reporting. A fixed continuity correction of 0.5 was applied where there

was a zero cell in calculating ORs. Two-sided p values of less than 0.05 were deemed to be statistically significant. All analyses were done with Stata version 14.0.

Results

A total of 9,877 records in bibliographic databases and 12 records from other sources were identified, with 22 studies included (Figure 1) [13-24, 28-37].

Study characteristics are summarized in Tables 1, 2 and Supplementary Table 1 (appendix pp 27). We identified 9 published studies that measured the impact of exposure to OAT on having ever received HCV antibody testing (ever OAT, 7 studies [14, 16-19, 28]; recent OAT, 7 studies [13, 14, 16-18, 20, 28]) or recently received HCV antibody testing (ever OAT, 3 studies [18, 28]; recent OAT, 4 studies [15, 18, 20, 28]; Table 2). We identified 5 published studies that measured the impact of exposure to OAT on having ever received HCV RNA testing (ever OAT, 5 studies [14, 16, 17, 28]; recent OAT, 5 studies [14, 16, 17, 20, 28]; Table 2) or recently received HCV RNA testing among those HCV antibody positive (ever OAT, 2 studies [28]; recent OAT, 2 studies [20, 28]; Table 2). We identified 8 published studies that measured the impact of exposure to OAT on having ever received HCV treatment among those HCV RNA detectable (ever OAT, 6 studies [14, 16, 20-22, 28]; recent OAT, 7 studies [14, 16, 20, 21, 23, 24, 28]; Table 2). We identified 9 published studies that measured the impact of exposure to recent OAT on DAA treatment completion (9 studies) and SVR (9 studies; Supplementary Table 1) (none of these studies included data on ever OAT) [29-37]. There was insufficient data on adherence to include this outcome.

Description of studies

Tables 1-2 and Supplementary Table 1 summarize the characteristics of the included studies undertaken in Australia (n=10), Canada (n=4), France (n=1), Georgia (n=1), Italy (n=1), Thailand (n=1), Ukraine (n=1), and the United States (n=2). Twenty studies were observational (12 cohort studies and 8 cross-sectional studies), 1 study was a clinical trial, and 1 study was

an interventional trial (Table 1). Definition of recent injecting drug use, proportion ever receiving OAT (52-88%), and proportion recently/currently receiving OAT (25-73%) varied across studies.

Risk of Bias

Risk of bias was serious in 21 studies and moderate in one study (Appendix, pp. 18-20). The domains that were most often associated with serious risk of bias included bias due to confounding and bias in the selection of participants. For all other risk of bias domains most studies were rated as being at low risk of bias. It was not appropriate to conduct sensitivity analyses (e.g. excluding studies at serious/critical risk of bias) because all but one study met this criteria.

Impact of OAT on HCV antibody testing

Across 8 studies, the proportion of people who ever received HCV antibody testing was between 33% and 94% (Table 2). Studies were pooled measuring the impact of ever having received OAT (7 studies) and recently/currently receiving OAT (7 studies) on having ever received HCV antibody testing (Figure 2). Random-effect meta-analysis of estimates demonstrated that having ever received OAT was associated with an increased odds of having ever received HCV antibody testing (OR=2.74; 95% CI 1.70, 4.40; $I^2=86.0\%$). Recent exposure to OAT was associated with an increased odds of having ever received HCV antibody testing (OR=2.26; 95% CI 1.80, 2.85; $I^2=37.2\%$)).

The proportion who recently received HCV antibody testing was between 48% and 71% (Table 2). We also pooled data from studies measuring the impact of ever having received OAT (3 studies) and recently/currently receiving OAT (4 studies) on having recently received HCV

antibody testing (Figure 2). Having ever received OAT was associated with an increased odds of recent HCV antibody testing (OR=2.12; 95% CI 1.07, 4.20; $I^2=75.7\%$). Recent exposure to OAT was associated with an increased odds of recent HCV antibody testing (OR=1.81; 95% CI 1.40, 2.34; $I^2=12.6\%$).

Impact of OAT on HCV RNA testing

The proportion of people who had ever received HCV RNA testing among those who were HCV antibody positive was between 35% and 89% (Table 2). Studies were pooled measuring the impact of ever having received OAT (5 studies) and recently/currently receiving OAT (5 studies) on having ever received HCV RNA testing (Figure 2). Having ever received OAT was associated with an increased odds of having ever received HCV RNA testing (OR=2.14; 95% CI 1.55, 2.95; $I^2=69.3\%$). Recent OAT exposure was associated with an increased odds of having ever received HCV RNA testing (OR=1.74; 95% CI 1.29, 2.35; $I^2=71.4\%$).

The proportion who had recently received HCV RNA testing was 44% in one study and 45% in the other study (Table 2). We pooled data from studies measuring the impact of ever having received OAT (2 studies) and having recently/currently receiving OAT (2 studies) on having recently received HCV RNA testing (Figure 2). Having ever received OAT was not associated with an increased odds of having recently received HCV RNA testing (OR= 2.38; 95% CI 0.94, 6.07; $I^2=90.5\%$). Having recently received OAT was associated with an increased odds of having received HCV RNA testing (OR=1.83; 95% CI 1.28, 2.61; $I^2=49.8\%$).

Impact of OAT on HCV treatment uptake

The proportion of people who had ever received HCV treatment among those who were HCV RNA detectable was between 6% and 72% (Table 2). Data from studies measuring the impact

of ever having received OAT (6 studies; DAA: 4 studies) and recently/currently receiving OAT (7 studies; DAA: 5 studies) on having ever received HCV treatment were pooled (Figure 3). The association of having ever received OAT and having ever received HCV treatment was not statistically significant (OR=1.53; 95% CI 0.92, 2.55; $I^2=86.3\%$). Recent OAT exposure was associated with an increased odds of having ever received HCV treatment (OR=1.56; 95% CI 1.07, 2.26; $I^2=82.3\%$). The intervention association strengthened and heterogeneity decreased when only studies in the DAA era were considered (6 studies; OR=1.83; 95% CI 1.51, 2.21, $I^2=0.0\%$). Having ever received OAT was associated with an increased odds of having ever received DAA HCV treatment (OR=2.15; 95% CI 1.67, 2.76, $I^2=0.0\%$) (4 studies).

Impact of OAT on HCV treatment completion and SVR

The proportion of people who had completed HCV treatment among those who initiated HCV treatment was between 65% and 100% and the proportion that had achieved SVR was between 64% and 94% (Supplementary Table 1). We pooled data from studies measuring the impact of recently/currently receiving OAT on having completed HCV treatment (9 studies) or having achieved an SVR (9 studies) (Figure 4). There was no impact of having recently received OAT on treatment completion (OR=1.25; 95% CI 0.57, 2.76, $I^2=54.2\%$) or SVR (OR=0.79; 95% CI 0.42, 1.51, $I^2=62.1\%$).

DISCUSSION

We found evidence of an association between recent OAT exposure and ever receiving OAT on HCV testing and treatment uptake among PWID. Recent OAT was not associated with DAA treatment completion or SVR. These data have important implications for clinical management and health policy, supporting the integration of services for the treatment of opioid dependence and HCV care among PWID.

OAT was associated with improvements in HCV testing and treatment uptake, consistent with literature demonstrating that OAT reduces harms across multiple health outcomes for people who are opioid dependent [38]. OAT improves engagement in HIV treatment, adherence, and virologic suppression [10]. OAT is also associated with reductions in injecting risk behavior [39], risk of HIV and HCV infections [11, 12], criminal activity [40], and all-cause [41] and overdose [41] mortality. It is unsurprising that current OAT was not associated with DAA treatment completion or SVR, given the high proportion of PWID who complete and respond to DAA therapy [42].

The mechanism behind the association between OAT and improvements in HCV testing and treatment is likely multifactorial, relating to the interplay between system-, provider-, social-, and patient-level factors. Most people receiving OAT attend drug treatment clinics or community health centers providing services other than OAT, including other medical care (including HCV), mental health services, and vocational and other assistance. People receiving OAT often have regular contact with health services with persistent cues for engagement and education [43], offering increased opportunities for engaging in HCV education, testing and treatment, particularly when services are integrated and on-site [44].

Qualitative interviews with people receiving and providing services in drug treatment clinics have highlighted key facilitators for engagement in HCV care [43, 45-50]. In drug treatment settings, engagement in HCV care is facilitated by existing relationships of trust between people receiving OAT and their healthcare providers [45-49], with HCV care providing opportunities to strengthen therapeutic relationships [50]. People using drug treatment services report that the provision of HCV testing and treatment on-site allows more immediate and accessible care [48]. This eliminates the need for often problematic and unsuccessful referral

from OAT to off-site hospital-based models of HCV care [48], which may be associated with negative, stigmatizing or discriminatory experiences [43, 46]. People receiving OAT also highlight that drug treatment clinics offer the potential for greater familiarity [46, 47, 50], flexibility [46], and convenience through on-site care (including reduced travel time and costs) [43, 46-50].

Integration of OAT and HCV has been shown to be highly acceptable to both clients and staff [51]. In a study of people with ongoing injecting drug use and opioid dependence offered HCV and buprenorphine treatment, 79% (53 of 67) not receiving OAT at baseline subsequently initiated buprenorphine during HCV therapy, with reductions in injecting risk observed among those receiving OAT [52]. Integration of OAT and HCV services can occur in a range of settings where people are already accessing health services (e.g. drug treatment clinics, HIV clinics, harm reduction services) in combination with different interventions (e.g. financial incentives, telemedicine, peer-based support) [13, 44]. No one size will fit all, with models of care requiring person-centric approaches. However, key barriers to HCV treatment among PWID must be addressed, include stigma, housing, criminalisation, and health care systems [54].

Major strengths of this study include synthesizing estimates for the association of OAT with components of the HCV cascade of care among PWID and the supplementary data included through contacting authors. Key limitations of the evidence include the small number of studies and that the majority of studies were from one country (Australia). Most studies were at serious risk of bias due to the potential for confounding and biases in the selection of participants into the studies. The control of confounders was limited and inconsistent across the studies. As such, unadjusted odds ratios had to be pooled and there were insufficient studies to perform a

meta-regression to explore sources of heterogeneity. The majority of studies identified were cross-sectional and the effect of residual confounding on OAT and components of the HCV cascade of care cannot be ruled out. People who accessed OAT may also have been more likely to have characteristics which may have led to increased HCV testing and treatment uptake. Since most studies were cross-sectional, it is possible that OAT use may not have preceded the outcome. This temporality of the association between the exposure (OAT) and outcome (HCV testing and treatment) is a limitation. We cannot, therefore, assume that OAT use commenced before, rather than after, HCV testing or treatment. The impact of OAT on HCV testing and treatment uptake at a population level will also be determined by the proportion of PWID within that population with opioid dependence. Although the majority of studies had a high proportion of participants with a history of opioid use, not all participants may have been opioid dependent and/or required OAT. This misclassification bias may have overestimated of the observed association between OAT and HCV outcomes.

In conclusion, this study demonstrated that recent OAT was associated with improvements in HCV testing and treatment uptake, supporting the integration of HCV services in drug treatment settings. This study also provides important information to inform mathematical modelling of interventions to enhance HCV care among PWID. Further work is needed to understand strategies to optimize HCV testing and treatment within drug treatment settings and improve the overall health of people who use drugs.

Funding

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The Australian National Drug and Alcohol Research Centre is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Australian National Drug and Alcohol Research Centre, UNSW Sydney, provided some funding towards the costs of this systematic review. JG is supported by an NHMRC Investigator Grant. LD is supported by an Australian National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship. LD and SL are supported by a National Institute of Health (NIH) National Institute on Drug Abuse (NIDA) grant (R01DA1104470). MH and PV acknowledge support from the NIHR HPRU in Evaluation of Interventions. PV acknowledges support from the HPRU in STIs and BBVs and National Institute for Drug Abuse [grant number R01 DA037773-01A1]. GD is supported by an NHMRC Practitioner Fellowship. BH is supported by an Australian National Health and Medical Council (NHMRC) Early Career Fellowship.

Conflict of interest:

JG reports grants and personal fees from Abbvie, Gilead Sciences, Merck, and Cepheid and grants from Hologic and Indivior, outside the submitted work. LD reports grants from Indivior and Seqirus, outside the submitted work. SL reports grants from Indivior, outside the submitted work. MH reports personal fees from Abbvie, personal fees from Gilead Sciences, personal fees from Merck, outside the submitted work. PR reports speaker fees and institutional research funding from Gilead Sciences, and speaking fees from MSD and Abbvie. GD reports grants from Gilead, Abbvie, Merck, and Bristol-Myers Squibb, personal fees from Gilead, Abbvie,

Merck, and non-financial support from Gilead, Abbvie, and Merck, outside the submitted work.

LT, AD, TS, PV, CF, KB, DG, HV, BH had no conflict of interest to declare.

Authors contributions

JG, LT, LD, SL, MH, PV, and BH conceived the scope of the review which was critically revised by all coauthors. Screening, review, data extraction and verification was done by JG, LT, LD, AD, TS, HV, and BH. Data analysis was done by LT and TS which was reviewed by JG. JG, LD, and BH drafted the first iteration of manuscript. All authors made substantial contributions to the critical review, editing, and revision of the manuscript. All authors approved the final version of the manuscript.

Acknowledgements

We would like to thank the individuals who responded to requests for additional data, including Sahar Bajis (The Kirby Institute, UNSW Sydney, Sydney, Australia); Olena Iakunchykova (State University of New York at Albany, Albany, United States) and Frederick Altice (Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, United States); Perrine Roux (Inserm, Paris, France); Carolyn Day (University of Sydney, Sydney, Australia); Jennifer Iversen (The Kirby Institute, UNSW Sydney, Sydney, Australia), Julie Bouscaillou, Tamar Kikvidze, Niklas Luhmann (Médecins du Monde, Paris, France), Kelli Wuerth and Brian Conway (Vancouver Infectious Diseases Centre, Vancouver, Canada), Lucio Boglione, Antonio Davolio (Unit of Infectious Diseases, University of Turin, Italy); Benjamin Eckhardt (NYU Medical Center, United States); Alain Litwin, Brianna Norton, Matthew Akiyama, Linda Agyemang (Albert Einstein College of Medicine and Montefiore Medical Center, New York City, United States); Chris Fraser, Marion Selfridge (Cool Aid Community Health Centre (CACHC), Victoria, Canada); Evan Cunningham (The

Kirby Institute, UNSW Sydney, Sydney, Australia); Leith Morris (School of Public Health, The University of Queensland, Australia).

REFERENCES

1. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* **2017**; 5(12): e1192-e207.
2. Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. *Addiction* **2019**; 114(1): 150-66.
3. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Ann Intern Med* **2017**; 166(9): 637-48.
4. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. *Journal of hepatology* **2019**.
5. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. *Hepatology* **2017**; 65(3): 804-12.
6. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. *J Hepatol* **2016**; 65(3): 524-31.
7. Kim D, Li AA, Gadiparthi C, et al. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. *Gastroenterology* **2018**; 155(4): 1154-63 e3.
8. WHO. Global health sector strategy on viral hepatitis 2016-2021.
9. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nature reviews Gastroenterology & hepatology* **2013**; 10(9): 553-62.
10. Low AJ, Mburu G, Welton NJ, et al. Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **2016**; 63(8): 1094-104.
11. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. *BMJ* **2012**; 345: e5945.
12. Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. *Addiction* **2018**; 113(3): 545-63.
13. Bajis S, Grebely J, Hajarizadeh B, et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. *J Viral Hepat* **2019**.
14. Butler K, Day C, Dietze P, Bruno R, Alati R, Burns L. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. *Journal of substance abuse treatment* **2015**; 58: 90-4.
15. Day CA, White B, Thein HH, et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. *AIDS care - psychological and socio-medical aspects of AIDS/HIV* **2008**; 20(1): 116-23.
16. Butler K, Larney S, Day CA, Burns L. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. *Drug and alcohol review* **2019**; 38(3): 264-9.

17. Iakunchykova O, Meteliuk A, Zelenev A, Mazhnaya A, Tracy M, Altice FL. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. *International journal of drug policy* **2018**; 57: 11-7.
18. Roux P, Castro DR, Ndiaye K, et al. Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. *Plos one* **2016**; 11(6).
19. Ti L, Kaplan K, Hayashi K, Suwannawong P, Wood E, Kerr T. Low rates of hepatitis C testing among people who inject drugs in Thailand: Implications for peer-based interventions. *Journal of Public Health (United Kingdom)* **2013**; 35(4): 578-84.
20. Valerio H, Alavi M, Silk D, et al. Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study. *Journal of Hepatology* **2019**; 70(1): e42.
21. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. *Journal of viral hepatitis* **2014**; 21(3): 198-207.
22. Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. *J Hepatol* **2019**; 70(1): 33-9.
23. Makarenko J, Artenie AA, Hoj S, et al. Transitioning from Interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs? *International Journal of Drug Policy* **2019**.
24. Socias ME, Ti L, Wood E, et al. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. *Liver Int* **2019**; 39(8): 1400-7.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* **2009**; 151(4): 264-9, W64.
26. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **2016**; 355: i4919.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* **2003**; 327(7414): 557-60.
28. Gibbs D, Larney S, Grebely J, et al. Hepatitis C virus cascade of care among people who inject drugs: A cross-sectional study of characteristics associated with HCV testing and treatment in Australia. In: 2019 NDARC Annual Research Symposium. Sydney, Australia, 2019.
29. Boglione L, Mornese Pinna S, De Nicolò A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. *Journal of viral hepatitis* **2017**; 24(10): 850-7.
30. Bouscaillou J, Kikvidze T, Butsashvili M, et al. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study. *Int J Drug Policy* **2018**; 62: 104-11.
31. Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program. *Open Forum Infect Dis* **2018**; 5(4): ofy048.
32. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *The Lancet Gastroenterology & Hepatology* **2018**; 3(3): 153-61.

33. Conway B, Raycraft T, Alimohammadi A, Bhutani Y, Kiani G, Hakobyan S. Efficacy of All-Oral HCV Therapy in People Who Inject Drugs (PWID). *Hepatology* **2016**; 64: 990A-A.
34. Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. *International journal of drug policy* **2017**; 47: 216-20.
35. Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. *International journal of drug policy* **2017**; 47: 196-201.
36. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. *International journal of drug policy* **2017**; 47: 209-15.
37. Selfridge M, Cunningham EB, Milne R, et al. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. *Int J Drug Policy* **2019**; 72: 106-13.
38. Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *Lancet* **2019**; 394(10208): 1560-79.
39. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database Syst Rev* **2011**; (8): CD004145.
40. Maglione MA, Raaen L, Chen C, et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. *J Subst Abuse Treat* **2018**; 89: 28-51.
41. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ* **2017**; 357: j1550.
42. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* **2018**; 3(11): 754-67.
43. Treloar C, Rance J, Grebely J, Dore GJ. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. *Drug Alcohol Depend* **2013**; 133(2): 529-34.
44. Socias ME, Karamouzian M, Parent S, Barletta J, Bird K, Ti L. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. *Int J Drug Policy* **2019**; 72: 146-59.
45. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. *AIDS Patient Care STDS* **2010**; 24(12): 753-62.
46. Harris M, Rhodes T, Martin A. Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. *Soc Sci Med* **2013**; 83: 19-26.
47. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. *J Viral Hepat* **2010**; 17(12): 839-44.
48. Treloar C, Rance J, Dore GJ, Grebely J, Group ES. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. *J Viral Hepat* **2014**; 21(8): 560-7.

49. Treloar C, Rance J, Group ES. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. *Int J Drug Policy* **2014**; 25(5): 865-70.
50. Rance J, Treloar C, Group ES. 'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. *Addiction* **2014**; 109(3): 452-9.
51. Chronister KJ, Lothian R, Gilliver R, Kearley J, Read P. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program. *Drug and alcohol review* **2019**; 38(2): 185-9.
52. Rosenthal ES, Silk R, Mathur P, et al. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. *Clin Infect Dis* **2020**.
53. Savic M, Best D, Manning V, Lubman DI. Strategies to facilitate integrated care for people with alcohol and other drug problems: a systematic review. *Subst Abuse Treat Prev Policy* **2017**; 12(1): 19.
54. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. *Harm Reduct J* **2013**; 10: 7.
55. Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *Lancet Glob Health* **2017**; 5(12): e1208-e20.

Table 1. Characteristics of the studies included in the analysis

	Number of studies (N=22) (%)	Number of study participants
Study design		
Observational, prospective	7 (32%)	2,016
Observational, retrospective	5 (23%)	1,539
Cross-sectional	8 (36%)	14,236
Clinical trials	2 (10%)	305
Study setting		
Community clinic	3 (14%)	437
Tertiary care	3 (14%)	431
Needle and syringe programs	5 (23%)	10,357
Mixed	6 (27%)	3,730
Other/not reported	5 (23%)	2,953
Number of Centres		
Single-centre	8 (35%)	1,359
Multicentre	14 (64%)	16,549
Definition of recent drug use¹		
During the past 1 month	3 (14%)	1,323
During the past 6 months	14 (64%)	6,223
During the past 12 months	2 (9%)	301
Ongoing or active drug use	4 (18%)	10,713
Definition of opioid substitution therapy¹		
Current	20 (91%)	8,574
Past 6 months	1 (5%)	345
Ever	8 (36%)	10,867

¹Total equals more than 100% due to 6 studies reporting multiple groups

Table 2. Characteristics of included studies and reported outcomes for HCV antibody, HCV RNA testing, and treatment uptake

HCV antibody testing																		
First author, year (Country)	Study design	Definition of recent injecting drug use	Total n	Age mean or median, year	Male (%)	Used opioids ever (%)	OAT ever (%)	OAT recently (%)	HCV antibody testing ever (%)	HCV antibody testing recently (%)	HCV antibody testing ever				Recent HCV antibody testing			
											no OAT ever	OAT ever	No recent OAT	OAT recently	No OAT ever	OAT ever	No recent OAT	OAT recently
Bajis, 2019 (Australia) [13]	Observational cohort	Previous 6 months	605	42	67%	NA	NA	65%	72%	NA	NA	NA	137/210 (65%)	297/395 (75%)	NA	NA	NA	NA
Butler, 2015 (Australia) [14]	Cross-sectional	Previous 6 months	854	40	64%	98%	74%	44%	94%	NA	201/233 (90%)	601/630 (95%)	441/477 (92%)	362/377 (96%)	NA	NA	NA	NA
Butler, 2019 (Australia) [16]	Cross-sectional	Previous 6 months	887	43	67%	97%	64%	38%	92%	NA	272/311 (87%)	540/571 (95%)	493/546 (90%)	323/341 (95%)	NA	NA	NA	NA
Day, 2008 (Australia) [15]	Cross-sectional	Previous 6 months	197	36	64%	NA	NA	68%	NA	71%	NA	NA	NA	NA	NA	NA	37/63 (59%)	103/134 (77%)
Gibbs, 2019 (Australia) [28]	Cross-sectional	Previous 6 months	905	43*	66%	95%	66%	38%	88%	57%	252/308 (82%)	541/594 (91%)	482/564 (85%)	314/341 (92%)	151/308 (49%)	364/594 (61%)	297/564 (53%)	220/341 (65%)
Iakunchykova, 2018 (Ukraine) [17]	Cross-sectional	Ongoing/active	1002	36*	76%	100%	52%	30%	83%	NA	215/481 (45%)	352/521 (68%)	215/481 (45%)	215/300 (72%)	NA	NA	NA	NA
Roux, 2016 (France) [18]	Intervention	Ongoing/active	202	30	77%	98%	87%	71%	82%	48%	16/57 (28%)	149/176 (85%)	27/57 (47%)	121/143 (85%)	7/57 (12%)	90/176 (51%)	16/57 (28%)	73/143 (51%)
Ti, 2013 (Thailand) [19]	Cross-sectional	Previous 6 months	427	38	81%	NA	76%	NA	33%	NA	13/104 (13%)	128/323 (40%)	NA	NA	NA	NA	NA	NA
Valerio, 2019 (Australia) [20]	Observational cohort	Previous 6 months	1147	43	65%	96%	82%	67%	85%	51%	139/205 (68%)	837/942 (89%)	284/373 (76%)	692/774 (89%)	84/205 (41%)	500/942 (53%)	159/373 (43%)	500/774 (65%)
HCV RNA testing																		
First author, year (Country)	Study design	Definition of recent injecting drug use	Total n	Age mean or median, year	Male (%)	Used opioids ever (%)	OAT ever (%)	OAT recently (%)	HCV RNA testing ever (%)	HCV RNA testing recently (%)	HCV RNA testing ever				Recent HCV RNA testing			
											no OAT ever	OAT ever	No recent OAT	OAT recently	no OAT ever	OAT ever	No recent OAT	OAT recently
Butler, 2015 (Australia) [14]	Cross-sectional	Previous 6 months	547	41	62%	99%	82%	49%	59%	NA	48/96 (50%)	275/451 (61%)	155/277 (56%)	168/270 (62%)	NA	NA	NA	NA
Butler, 2019 (Australia) [16]	Cross-sectional	Previous 6 months	481	44	67%	98%	77%	47%	89%	NA	97/113 (86%)	332/368 (90%)	225/257 (88%)	203/224 (91%)	NA	NA	NA	NA
Gibbs, 2019 (Australia) [28]	Cross-sectional	Previous 6 months	796	43*	66%	95%	68%	39%	68%	45%	132/252 (52%)	405/541 (75%)	301/482 (62%)	238/314 (76%)	84/252 (33%)	272/541 (50%)	199/482 (41%)	158/314 (50%)
Iakunchykova, 2018 (Ukraine) [17]	Cross-sectional	Ongoing/active	1002	37*	76%	100%	52%	30%	35%	NA	126/481 (26%)	220/521 (42%)	126/481 (26%)	145/300 (48%)	NA	NA	NA	NA

Valerio, 2019 (Australia) [20]	Observational cohort	Previous 6 months	796	45	66%	99%	89%	75%	77%	45%	55/86 (64%)	559/710 (79%)	144/202 (71%)	470/594 (79%)	32/86 (37%)	329/710 (46%)	79/202 (39%)	282/594 (47%)	
HCV treatment uptake																			
											HCV treatment uptake								
First author, year (Country)	Study design	Definition of recent injecting drug use	Total number of participants	Age mean or median, year	Male (%)	Used opioids ever (%)	OAT ever (%)	OAT recently (%)	HCV treatment ever (%)	no OAT ever	OAT ever	No recent OAT	OAT recently						
Butler, 2015 (Australia) [14]	Cross-sectional	Previous 6 months	179	41	61%	98%	88%	57%	20%	6/21 (29%)	29/158 (18%)	13/77 (17%)	18/102 (18%)						
Butler, 2019 (Australia) [16]	Cross-sectional	Previous 6 months	289	43	72%	99%	77%	45%	32%	15/68 (22%)	77/223 (35%)	37/159 (23%)	55/130 (42%)						
Gibbs, 2019 (Australia) [28]	Cross-sectional	Previous 6 months	334	44*	71%	98%	81%	50%	72%	35/62 (56%)	204/271 (75%)	108/168 (64%)	131/166 (79%)						
Iversen, 2014 (Australia) [21]	Cross-sectional	Ongoing/active	9478	35	64%	NA	81%	50%	6%	128/1767 (7%)	468/7683 (6%)	128/1767 (7%)	283/4743 (6%)						
Iverson, 2019 (Australia) [22]	Cross-sectional	Previous 1 month	486	NA	66%	NA	76%	NA	41%	32/117 (27%)	165/369 (45%)	NA	NA						
Makarenko, 2019 (Canada) [23]	Observational cohort	Previous 6 months	308	42	85%	NA	NA	33%	26%	NA	NA	46/206 (22%)	34/102 (33%)						
Socias, 2019 (Canada) [24]	Observational cohort	Previous 6 months	611	47	60%	NA	NA	56%	13%	NA	NA	25/266 (9%)	53/345 (15%)						
Valerio, 2019 (Australia) [20]	Observational cohort	Previous 6 months	620	44	70%	98%	89%	74%	64%	29/69 (42%)	364/551 (66%)	82/159 (52%)	311/461 (67%)						

Figure 1. PRISMA flowchart

Figure 2. Forest plots examining the association between OAT and HCV antibody and RNA testing

Figure 3. Forest plots examining the association between OAT and HCV treatment uptake

Figure 4. Forest plots examining the association between OAT and HCV treatment completion and SVR